NYSE:HRC - Hill-Rom Stock Price, Forecast & News

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Hill-Rom announced a quarterly dividend on Wednesday, February 26th. Investors of record on Monday, March 23rd will be paid a dividend of $0.22 per share on Tuesday, March 31st. This represents a $0.88 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Friday, March 20th. This is an increase from Hill-Rom's previous quarterly dividend of $0.21. View Hill-Rom's Dividend History.

Hill-Rom Holdings, Inc. (NYSE:HRC) announced its earnings results on Friday, January, 24th. The medical technology company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. The medical technology company earned $685 million during the quarter, compared to analyst estimates of $684.01 million. Hill-Rom had a return on equity of 21.87% and a net margin of 5.15%. The company's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.02 earnings per share. View Hill-Rom's Earnings History.

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Hill-Rom.

Hill-Rom issued an update on its FY20 earnings guidance on Friday, January, 24th. The company provided EPS guidance of $5.50-5.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.52. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.94 billion.

3 equities research analysts have issued twelve-month price targets for Hill-Rom's shares. Their forecasts range from $116.00 to $138.00. On average, they anticipate Hill-Rom's share price to reach $127.50 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Price Targets for Hill-Rom.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

News headlines about HRC stock have trended very negative on Friday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hill-Rom earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Hill-Rom.

Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO).

Hill-Rom's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (2.76%), State Street Corp (2.48%), Bank of New York Mellon Corp (1.63%), Bank of Montreal Can (1.58%), Geode Capital Management LLC (1.41%) and Bank of America Corp DE (1.24%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

HRC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Jennison Associates LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Credit Suisse AG, Lord Abbett & CO. LLC, AQR Capital Management LLC and State Street Corp. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

HRC stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., AXA, State of New Jersey Common Pension Fund D, Acadian Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Hill-Rom.

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HRC stock can currently be purchased for approximately $96.82.

Hill-Rom has a market capitalization of $6.49 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.

The official website for Hill-Rom is http://www.hill-rom.com/.

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]